Predictors of renal complications in pediatric patients with type 1 diabetes mellitus: A prospective cohort study

d’Annunzio, Giuseppe; Beccaria, A; Pistorio, Angela; Verrina, Enrico; Minuto, Nicola; Pontremoli, Roberto; Valle, Alberto La; Maghnie, Mohamad

doi:10.1016/j.jdiacomp.2018.02.007

Cited by 5 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Type 1 DM Albuminuria is the characteristic first indication of DN, followed by a loss of kidney function and, eventually, ESKD [54]. Despite the fact that microalbuminuria is usually used to predict DN, only 30% of people advance to overt proteinuria.…”

Section: Diabetic Kidney Diseasementioning

confidence: 99%

Urinary Epidermal Growth Factor: A Promising “Next Generation” Biomarker in Kidney Disease

et al. 2022

View full text Add to dashboard Cite

Background: The epidermal growth factor (EGF) is a globular protein that is generated in the kidney, especially in the loop of Henle and the distal convoluted tubule. While EGF is nonexistent or hardly detectable in plasma, it is present in normal people’s urine. Until now, risk stratification and chronic kidney disease (CKD) diagnosis have relied on estimated glomerular filtration rate (eGFR) and urine albumin/creatinine ratio (uACR), both of which reflect glomerular function or impairment. Tubular dysfunction, on the other hand, may also be associated with renal failure. Summary: Because decreased urine EGF (uEGF) indicates tubular atrophy and interstitial fibrosis, this biomarker, together with eGFR and uACR, may be employed in the general population for risk assessment and diagnosis of CKD. uEGF levels have been shown to correlate with intrarenal EGF mRNA expression and have been found to decrease in a variety of glomerular and non-glomerular kidney disorders. Key Message: uEGF, uEGF/creatinine, or uEGF/monocyte chemotactic peptide-1 are possible “new generation” biomarkers linked to a variety of kidney diseases that deserve further investigation as a single biomarker or as part of a multi-biomarker panel.

show abstract

Section: Diabetic Kidney Diseasementioning

confidence: 99%

Urinary Epidermal Growth Factor: A Promising “Next Generation” Biomarker in Kidney Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). and eventually leading to end-stage renal disease [3]. In addition to glomerular injury, renal tubulointerstitial changes are a major feature of diabetes nephropathy as well, representing an important predictor of renal dysfunction [4].…”

Section: Introductionmentioning

confidence: 99%

The next generation: Urinary epidermal growth factor is associated with an early decline in kidney function in children and adolescents with type 1 diabetes mellitus

Ledeganck

Brinker

Peeters

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Micro-albuminuria is considered an early clinical sign of diabetes nephropathy, however, early decrease of glomerular filtration can be present years before the presence of microalbuminuria. In this study, we explored whether urinary epidermal growth factor (uEGF) might serve as an early marker of diabetes nephropathy compared to microalbuminuria in children and adolescents. Methods: Children with type 1 diabetes mellitus (n = 158) and healthy controls (n = 40) were included in this study. Serum and urine samples were collected three times with an interval of at least one month to determine creatinine (serum and urine), epidermal growth factor and albumin (urine). Demographic data and routine lab values were extracted out of the electronic patient files. Results: uEGF was significantly lower in children with T1DM compared to healthy controls (p = 0.032). A relatively lower glomerular filtration rate (eGFR) was associated with a decreased uEGF (p < 0.001). uEGF was independently associated with eGFR in a multivariate analysis. Conclusion:This study provides evidence that uEGF can serve as an early marker of diabetes nephropathy in children and adolescents.

show abstract

“…It alleviates vasoconstriction, fibrosis, oxidative stress, water and salt retention promoted by angiotensin II. Angiotensin converting enzyme 2 hydrolyses angiotensin II and angiotensin I; generating angiotensin ( 1 - 7 ) and angiotensin ( 1 - 9 ) respectively (Figure 1). Acting through the ACE2 - angiotensin ( 1 - 7 ) – Mas axis, angiotensin ( 1 - 7 ) endogenously counteracts the deleterious effects of angiotensin II and affords protection to kidneys.…”

Section: Introductionmentioning

confidence: 99%

“…Schematic representation of the nephroprotective mechanism of angiotensin converting enzyme 2 and angiotensin ( 1 - 7 ). ACE2 - angiotensin converting enzyme 2.…”

Section: Introductionmentioning

confidence: 99%

“…The first clinical sign of diabetic nephropathy is albuminuria in the range of 30 - 300 mg/day, which gradually increases as the renal function declines. Since 1980’s, albuminuria has been a diagnostic standard for diabetic nephropathy and is still being considered a risk factor for renal complications among the diabetics ( 7 - 9 ). Lately, however, its suitability for diagnosis and prognosis has been questioned as it emerged that about 50% of diabetic patients with renal impairment remain normoalbuminuric ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy

Akankwasa

Liu

Cheng

et al. 2018

Biochem. med. (Online)

View full text Add to dashboard Cite

Urinary angiotensin converting enzyme 2 (ACE2) is significantly increased in diabetes and diabetic nephropathy. While studies on its clinical significance are still underway, its urinary expression, association with metabolic and renal parameters has been in the recent past considerably studied. The recent studies have demystified urine ACE2 in many ways and suggested the roles it could play in the management of diabetic nephropathy. In all studies the expression of urinary ACE2 was determined by enzyme activity assay and/with the quantification of ACE2 protein and mRNA by methods whose reliability are yet to be evaluated. This review summarizes recent findings on expression of urinary ACE2, examines its relationship with clinical parameters and highlights possible applications in management of diabetic nephropathy.

show abstract

Predictors of renal complications in pediatric patients with type 1 diabetes mellitus: A prospective cohort study

Cited by 5 publications

References 35 publications

Urinary Epidermal Growth Factor: A Promising “Next Generation” Biomarker in Kidney Disease

Urinary Epidermal Growth Factor: A Promising “Next Generation” Biomarker in Kidney Disease

The next generation: Urinary epidermal growth factor is associated with an early decline in kidney function in children and adolescents with type 1 diabetes mellitus

A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy

Contact Info

Product

Resources

About